Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRN | P28799 | 1/20 | 0.43 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.43 |
| ▸ | PSMB5 | P28074 | 3/20 | 0.42 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.42 |
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MMP3 | P08254 | 1/20 | 0.41 |
| ▸ | MME | P08473 | 1/20 | 0.40 |
| ▸ | ANPEP | P15144 | 1/20 | 0.40 |
| ▸ | MMP8 | P22894 | 3/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | HTRA1 | Q92743 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4335685 | 0.87 | NPC1 (0.44) | MMEMMP8NPC1RAB9A | |
| SCHEMBL4338140 | 0.87 | PSMB8 (0.44) | PSMB5PSMB8MMEANPEPMMP8 | |
| SCHEMBL4333077 | 0.85 | PSMB8 (0.47) | PSMB5PSMB8MMP2MMEANPEP | |
| SCHEMBL4340539 | 0.84 | TRPA1 (0.42) | MMP8TRPA1NPC1RAB9A | |
| SCHEMBL4335651 | 0.81 | TRPA1 (0.44) | MMP1MMP8TRPA1NPC1RAB9A | |
| SCHEMBL1153189 | 0.80 | ANPEP (0.40) | GRNSORT1PSMB5PSMB8MMP1 | |
| SCHEMBL4337146 | 0.79 | CTSL (0.41) | PSMB5PSMB8MMP1MMP2MMP3 | |
| SCHEMBL4330929 | 0.79 | TRPA1 (0.41) | MMP1MMP8TRPA1NPC1RAB9A | |
| SCHEMBL11102570 | 0.79 | TAAR1 (0.43) | PSMB5PSMB8MMP1MMP2MMP3 | |
| SCHEMBL4344350 | 0.78 | OPRK1 (0.48) | MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612236-B2 | Method for producing optically active bisamidoalcohol compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-11-03 | — | — | US | disclosed |
| US-20070100163-A1 | Reacting an optically active aminoalcohol compound with a diester compound in the presence of a lithium compound wherein the lithium compound is selected from lithium hydroxide, a lithium alkoxide and a lithium halide; product can be efficiently and inexpensively produced | SUMITOMO CHEMICAL COMPANY, LIMITED | 2007-05-03 | — | — | US | disclosed |
| EP-1698616-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE BISAMIDO ALCOHOL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2006-09-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070100163-A1 | Reacting an optically active aminoalcohol compound with a diester compound in the presence of a lithium compound wherein the lithium compound is selected from lithium hydroxide, a lithium alkoxide and a lithium halide; product can be efficiently and inexpensively produced | CCNL2, ARL1, ACSL3 | GRN 3969/4885SORT1 4851/4885PSMB5 4430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.